Xcout IntelAxsome Therapeutics
Axsome Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative treatments for central nervous system (CNS) disorders, primarily focusing on the United States market. Its pipeline includes AXS-05, a therapeutic candidate for major depressive disorder and treatment-resistant depression, which is also currently in Phase III clinical trials for Alzheimer's disease agitation and has completed Phase II studies for smoking cessation. The company is also advancing AXS-07, an experimental, rapidly absorbed, oral medication with a multi-mechanistic profile, which has successfully concluded two Phase III trials for the acute treatment of migraine. Another key asset is AXS-12, a selective and potent norepinephrine reuptake inhibitor, presently in Phase III development for narcolepsy. Furthermore, AXS-14, an investigational oral medicine, is undergoing Phase III trials for fibromyalgia. Axsome Therapeutics maintains a research collaboration with Duke University to further evaluate AXS-05 for smoking cessation. The company was founded in 2012 and is headquartered in New York, New York.
Subscribe to see Axsome Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Axsome Therapeutics at a glance
Axsome Therapeutics is a biopharmaceuticals company headquartered in New York City, United States. It is publicly listed (0HKF) with a market capitalisation of $11.5B. Xcout tracks 12 named people at Axsome Therapeutics, including Mark L. Jacobson (Chief Operating Officer). Xcout recorded 134 job postings from Axsome Therapeutics in the last 90 days, naming tools such as Salesforce, Power BI, Tableau.
Axsome Therapeutics leadership
- Mark L. JacobsonChief Operating Officer
- Nick PizzieChief Financial Officer
- Ari MaizelChief Commercial Officer
- Herriot TabuteauFounder, Chairman, Chief Executive Officer & President
- Darren OplandDirector of Corporate Communications
- Hunter MurdockGeneral Counsel & Secretary
6 more named people on record for Axsome Therapeutics, with roles, board committees and tenure — see the full roster →
Axsome Therapeutics funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $52M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Axsome Therapeutics
Xcout recorded 134 job postings from Axsome Therapeutics in the last 90 days, from a hiring record Xcout has kept since May 2026.
Tools named in Axsome Therapeutics's job postings
The weekly hiring trend, the roles and locations behind it — see Axsome Therapeutics's hiring signals →
Hiring vs the trend
Based on 91 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 158 scale-up healthcare companies.
This describes a hiring pattern — how often Axsome Therapeutics’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Tech stack
Axsome Therapeutics competitors
A few of Axsome Therapeutics's closest competitors — see the full list of competitors and alternatives →
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder. Beyond its current commercial use, BXCL501 is also undergoing further clinical investigation. Studies are underway to assess its efficacy for agitation in individuals with Alzheimer's disease, as an add-on therapy for major depressive disorder, and for use in community settings to address agitation linked to bipolar disorders and schizophrenia. Furthermore, BioXcel is advancing BXCL502, a candidate therapy targeting chronic agitation prevalent in dementia patients. Another key pipeline asset is BXCL701, an orally administered systemic innate immunity activator currently under investigation. This compound shows promise for treating aggressive prostate cancer and advanced solid tumors that have either become resistant to checkpoint inhibitors or have not yet received such treatment. Established in 2017, the company maintains its headquarters in New Haven, Connecticut.
Biohaven is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments across key therapeutic areas. Headquartered with operations in New Haven, Connecticut, the company advances innovative neuroscience and specialty therapeutics.
Nexalis Health, Inc. (operating as Nexalis Therapeutics) is a clinical-stage biopharmaceutical company that develops oral and inhaled therapies for pain management and mental health conditions. Its pipeline includes three drug candidates addressing treatment-resistant depression, breakthrough cancer pain, and panic disorder.
Tortugas Neuroscience is a drug discovery and biopharmaceutical company headquartered in Framingham, Massachusetts. The company focuses on advancing innovative neuroscience therapeutics.
Cerevel Therapeutics was a U.S. biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders, including schizophrenia, Parkinson’s disease, and Alzheimer’s disease. Its therapies were intended to serve patients with serious central nervous system conditions and the healthcare providers treating them.
Object Pharma is a privately held biopharmaceutical company headquartered in Aliso Viejo, California, founded in 2018. The company is dedicated to developing novel treatments for mental health disorders and manufactures botulinum toxin products for accredited research use.
Get Axsome Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Axsome Therapeutics in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access